Nonfasting for routine lipid testing from evidence to action

JAMA Internal Medicine

Volumn 176, Issue 7, 2016, Pages 1005-1006

  Mora, Samia ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; CHOLESTEROL; LIPOPROTEIN;

CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; DIET RESTRICTION; ECONOMIC ASPECT; FOLLOW UP; HEALTH CARE POLICY; HUMAN; LABORATORY TEST; LIPID ANALYSIS; POSTPRANDIAL STATE; PRACTICE GUIDELINE; PRIORITY JOURNAL; RISK ASSESSMENT; SCREENING TEST; SHORT SURVEY; ALGORITHM; BLOOD; CARDIOVASCULAR DISEASE; EUROPE; FEMALE; MALE; MEDICAL SOCIETY; NUTRITION; PROGNOSIS; STANDARDS; UNITED STATES;

ALGORITHMS; CARDIOVASCULAR DISEASES; CHOLESTEROL; CHOLESTEROL, HDL; CHOLESTEROL, LDL; EUROPE; FASTING; FEMALE; HUMANS; LIPOPROTEINS; MALE; NUTRITION SURVEYS; POSTPRANDIAL PERIOD; PRACTICE GUIDELINES AS TOPIC; PROGNOSIS; SOCIETIES, MEDICAL; TRIGLYCERIDES; UNITED STATES;

EID: 84979041818     PISSN: 21686106     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamainternmed.2016.1979     Document Type: Short Survey

References (10)

1. Rifai N, Young IS, Nordestgaard BG, et al. Nonfasting sample for the determination of routine lipid profile: Is it an idea whose time has come? Clin Chem. 2016;62(3):428-435.
2. Nordestgaard BG, Langsted A, Mora S, et al. Fasting is not routinely required for determination of a lipid profile: clinical and laboratory implications including flagging at desirable concentration cut-points: A joint consensus statement from the EAS and EFLM. Eur Heart J. In press.
3. Mora S, Rifai N, Buring JE, Ridker PM. Fasting compared with nonfasting lipids and apolipoproteins for predicting incident cardiovascular events. Circulation. 2008;118(10): 993-1001.
4. Di Angelantonio E, Sarwar N, Perry P, et al; Emerging Risk Factors Collaboration. Major lipids, apolipoproteins, and risk of vascular disease. JAMA. 2009;302(18):1993-2000.
5. NICE clinical guideline CG181. Lipid modification: Cardiovascular risk assessment and the modification of blood lipids for the primary and secondary prevention of cardiovascular disease; 2014. https://www.nice.org.uk/guidance/cg181. Accessed March 17, 2016.
6. Stone NJ, Robinson JG, Lichtenstein AH, et al; American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;129(25) (suppl2):S1-S45.
7. Anderson TJ, Grégoire J, Hegele RA, et al. 2012 update of the Canadian Cardiovascular Society guidelines for the diagnosis and treatment of dyslipidemia for the prevention of cardiovascular disease in the adult. Can J Cardiol. 2013;29(2): 151-167.
8. Reiner Z, Catapano AL, De Backer G, et al; European Association for Cardiovascular Prevention & Rehabilitation; ESC Committee for Practice Guidelines (CPG) 2008-2010 and 2010-2012 Committees. ESC/EAS guidelines for the management of dyslipidaemias: The task force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J. 2011;32 (14):1769-1818.
9. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) final report. Circulation. 2002; 106(25):3143-3421.
10. White KT, MoorthyMV, Akinkuolie AO, et al. Identifying an optimal cutpoint for the diagnosis of hypertriglyceridemia in the nonfasting state. Clin Chem. 2015;61(9):1156-1163.